secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092262
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026
--------------------------------------------------------------------------------

- Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.
- Cash and investments $280.2M at June 30, 2024; expected to fund operations through Phase 3 wet AMD topline data in 2026.
- Phase 3 LUGANO wet AMD trial on track for first patient dosing in 2024; LUCIA trial to follow shortly.
- Positive 12-month DAVIO 2 data: DURAVYU non-inferior to aflibercept in visual acuity; majority supplement-free.
- Phase 2 VERONA (DME) fully enrolled; topline data anticipated Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/0000950170-24-092262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024092262/eypt-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer